IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC

Overview

cited authors

Socinski, M. A.; Rittmeyer, A.; Shapovalov, D.; Orlandi, F.; McCleod, M.; Soo, R. A.; Palmero, R.; Kozuki, T.; Migliorino, M. R.; Koynov, K. D.; Berard, H.; Hughes, B. G. M.; Yu, W.; Graupner, V.; Sun, S. W.; Kowanetz, M.; Hoang, T.; Lin, W.; Jotte, R. M.

authors

Socinski, Mark A., MD

Publication Date

October 1, 2018

webpage

Web of Science

published in

ANNALS OF ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.